secwatch.observer — SEC 8-K summary
======================================

Issuer:     HeartSciences Inc. (HSCS)
CIK:        0001468492
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001213900-24-022613
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HeartSciences Q3 cash $7.1M; licenses AI-ECG from Mount Sinai; FDA 510(k) path
------------------------------------------------------------------------------

- No significant revenue in Q3 FY2024; cash $7.1M, shareholders' equity $8.6M as of Jan 31, 2024.
- Raised $9.2M net from stock sales and converted $1.1M debt to equity during quarter.
- Licensed AI-ECG algorithms and IP from Icahn School of Medicine at Mount Sinai; Mount Sinai became largest shareholder.
- FDA pathway changed to 510(k) for MyoVista device; targeting FDA clearance around calendar year-end 2024.
- Peer-reviewed study showed MyoVista AI-ECG outperformed standard screening for heart disease in diabetic patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468492/000121390024022613/0001213900-24-022613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468492/000121390024022613/ea0201847-8k_hearttest.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-022613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer